Premium
Therapeutic cannabinoids in multiple sclerosis: immunomodulation revisited
Author(s) -
Constantinescu C. S.,
Gershkovich P.
Publication year - 2018
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/ene.13658
Subject(s) - medicine , multiple sclerosis , neuroscience , synthetic cannabinoids , intensive care medicine , psychiatry , cannabinoid , receptor , biology
Cannabinoids are compounds with pleiotropic properties that act on the cannabinoid receptors, CB1 and CB2, and are divided into endocannabinoids, the endogenous ligands of these receptors, synthetic cannabinoids and phytocannabinoids. The latter are derived from the plant Cannabis sativa. The therapeutic and psychoactive properties of this plant have been observed and used for centuries. Of the over 60 compounds that are unique to Cannabis sativa, the substances that have been attributed the greatest therapeutic potential are Δ - tetrahydrocannabinol (THC) and cannabidiol (CBD), both of which, used alone or combined with each other, have become approved drugs. This article is protected by copyright. All rights reserved.